Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis

摘要

Background:Lung cancer with ovarian metastasis or adnexal metastasis harboring anaplastic lymphoma kinase (ALK) gene translocation is rare. Crizotinib, a novel ALK tyrosine kinase inhibitor, has already shown an impressive single-agent activity in ALK positive lung cancer.